Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 68 entries
Sorted by: Best Match Show Resources per page
Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?.

Cancers

Gomez-Brouchet A, Gilhodes J, Acker NV, Brion R, Bouvier C, Assemat P, Gaspar N, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, Pinieux G, Mascard E, Gouin F, Brousset P, Tabone MD, Jimenez M, Le Deley MC, Blay JY, Brugieres L, Piperno-Neumann S, Rédini F.
PMID: 33498676
Cancers (Basel). 2021 Jan 23;13(3). doi: 10.3390/cancers13030423.

Biological and histopathological techniques identified osteoclasts and macrophages as targets of zoledronic acid (ZA), a therapeutic agent that was detrimental for patients in the French OS2006 trial. Conventional and multiplex immunohistochemistry of microenvironmental and OS cells were performed on...

Cite
Gomez-Brouchet A, Gilhodes J, Acker NV, et al. Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. Cancers (Basel). 2021;13(3)doi: 10.3390/cancers13030423.
Gomez-Brouchet, A., Gilhodes, J., Acker, N. V., Brion, R., Bouvier, C., Assemat, P., Gaspar, N., Aubert, S., Guinebretiere, J. M., Marie, B., Larousserie, F., Entz-Werlé, N., Pinieux, G., Mascard, E., Gouin, F., Brousset, P., Tabone, M. D., Jimenez, M., Le Deley, M. C., Blay, J. Y., Brugieres, L., Piperno-Neumann, S., & Rédini, F. (2021). Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. Cancers, 13(3), . https://doi.org/10.3390/cancers13030423
Gomez-Brouchet, Anne, et al. "Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?." Cancers vol. 13,3 (2021). doi: https://doi.org/10.3390/cancers13030423
Gomez-Brouchet A, Gilhodes J, Acker NV, Brion R, Bouvier C, Assemat P, Gaspar N, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, Pinieux G, Mascard E, Gouin F, Brousset P, Tabone MD, Jimenez M, Le Deley MC, Blay JY, Brugieres L, Piperno-Neumann S, Rédini F. Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. Cancers (Basel). 2021 Jan 23;13(3). doi: 10.3390/cancers13030423. PMID: 33498676; PMCID: PMC7866157.
Copy Download .nbib Format: NLM
Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial.

PloS one

Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C.
PMID: 34941934
PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021.

BACKGROUND: Chronic Lung Allograft Dysfunction (CLAD) is a major obstacle for long term survival after lung transplantation (LTx). Besides Bronchiolitis Obliterans Syndrome, two other phenotypes of CLAD, restrictive allograft syndrome (RAS) and mixed phenotype, have been described. Trials to...

Cite
Gottlieb J, Verleden GM, Perchl M, et al. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021;16(12):e0260881doi: 10.1371/journal.pone.0260881.
Gottlieb, J., Verleden, G. M., Perchl, M., Valtin, C., Vallee, A., Brugière, O., & Bravo, C. (2021). Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PloS one, 16(12), e0260881. https://doi.org/10.1371/journal.pone.0260881
Gottlieb, Jens, et al. "Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial." PloS one vol. 16,12 (2021): e0260881. doi: https://doi.org/10.1371/journal.pone.0260881
Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021. PMID: 34941934; PMCID: PMC8700042.
Copy Download .nbib Format: NLM
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.

Hepatology international

Illiano M, Colinard M, Taque S, Mallon B, Larue C, Laithier V, Vérité-Goulard C, Sudour-Bonnange H, Faure-Conter C, Coze C, Aerts I, De Maricourt CD, Paillard C, Branchereau S, Brugières L, Fresneau B.
PMID: 34506008
Hepatol Int. 2021 Sep 10; doi: 10.1007/s12072-021-10251-1. Epub 2021 Sep 10.

BACKGROUND AND AIMS: Prognosis of hepatoblastoma patients has increased with cisplatin-based chemotherapy and high-quality resection including liver transplant. Consequently current risk-adapted therapeutic strategy aims to reduce long-term side effects in patients with standard risk disease.METHODS: We report long-term mortality...

Cite
Illiano M, Colinard M, Taque S, et al. Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies. Hepatol Int. 2021;doi: 10.1007/s12072-021-10251-1.
Illiano, M., Colinard, M., Taque, S., Mallon, B., Larue, C., Laithier, V., Vérité-Goulard, C., Sudour-Bonnange, H., Faure-Conter, C., Coze, C., Aerts, I., De Maricourt, C. D., Paillard, C., Branchereau, S., Brugières, L., & Fresneau, B. (2021). Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies. Hepatology international, . https://doi.org/10.1007/s12072-021-10251-1
Illiano, M, et al. "Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies." Hepatology international vol. (2021). doi: https://doi.org/10.1007/s12072-021-10251-1
Illiano M, Colinard M, Taque S, Mallon B, Larue C, Laithier V, Vérité-Goulard C, Sudour-Bonnange H, Faure-Conter C, Coze C, Aerts I, De Maricourt CD, Paillard C, Branchereau S, Brugières L, Fresneau B. Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies. Hepatol Int. 2021 Sep 10; doi: 10.1007/s12072-021-10251-1. Epub 2021 Sep 10. PMID: 34506008.
Copy Download .nbib Format: NLM
Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report.

Frontiers in endocrinology

Del Sindaco G, Berlanga P, Brugières L, Thebault E, Mantovani G, Wicart P, Linglart A.
PMID: 34335473
Front Endocrinol (Lausanne). 2021 Jul 16;12:698963. doi: 10.3389/fendo.2021.698963. eCollection 2021.

Aneurysmal bone cysts (ABCs) are rare benign pseudotumoral bone lesions with potential aggressive behavior due to the extensive destruction of surrounding bone. Traditionally, these tumors were treated with open surgery, but there is more and more a shift to...

Cite
Del Sindaco G, Berlanga P, Brugières L, et al. Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. Front Endocrinol (Lausanne). 2021;12:698963doi: 10.3389/fendo.2021.698963.
Del Sindaco, G., Berlanga, P., Brugières, L., Thebault, E., Mantovani, G., Wicart, P., & Linglart, A. (2021). Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. Frontiers in endocrinology, 12698963. https://doi.org/10.3389/fendo.2021.698963
Del Sindaco, Giulia, et al. "Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report." Frontiers in endocrinology vol. 12 (2021): 698963. doi: https://doi.org/10.3389/fendo.2021.698963
Del Sindaco G, Berlanga P, Brugières L, Thebault E, Mantovani G, Wicart P, Linglart A. Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. Front Endocrinol (Lausanne). 2021 Jul 16;12:698963. doi: 10.3389/fendo.2021.698963. eCollection 2021. PMID: 34335473; PMCID: PMC8322664.
Copy Download .nbib Format: NLM
Additional Data on the Distribution of Cercopithecus (lhoesti) solatus.

Folia primatologica; international journal of primatology

Brugière D, Gautier J, Lahm S.
PMID: 9751841
Folia Primatol (Basel). 1998 Oct;69(5):331-336. doi: 10.1159/000021648.

No abstract available.

Cite
Brugière D, Gautier J, Lahm S. Additional Data on the Distribution of Cercopithecus (lhoesti) solatus. Folia Primatol (Basel). 1998;69(5):331-336doi: 10.1159/000021648.
Brugière, D., Gautier, J., & Lahm, S. (1998). Additional Data on the Distribution of Cercopithecus (lhoesti) solatus. Folia primatologica; international journal of primatology, 69(5), 331-336. https://doi.org/10.1159/000021648
Brugière, et al. "Additional Data on the Distribution of Cercopithecus (lhoesti) solatus." Folia primatologica; international journal of primatology vol. 69,5 (1998): 331-336. doi: https://doi.org/10.1159/000021648
Brugière D, Gautier J, Lahm S. Additional Data on the Distribution of Cercopithecus (lhoesti) solatus. Folia Primatol (Basel). 1998 Oct;69(5):331-336. doi: 10.1159/000021648. PMID: 9751841.
Copy Download .nbib Format: NLM
Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium.

Neuro-oncology advances

Guerrini-Rousseau L, Varlet P, Colas C, Andreiuolo F, Bourdeaut F, Dahan K, Devalck C, Faure-Conter C, Genuardi M, Goldberg Y, Kuhlen M, Moalla S, Opocher E, Perez-Alonso V, Sehested A, Slavc I, Unger S, Wimmer K, Grill J, Brugières L.
PMID: 32642664
Neurooncol Adv. 2019 Dec 02;1(1):vdz033. doi: 10.1093/noajnl/vdz033. eCollection 2019.

BACKGROUND: Malignant brain tumors (BT) are among the cancers most frequently associated with constitutional mismatch repair deficiency (CMMRD), a rare childhood cancer predisposition syndrome resulting from biallelic germline mutations in mismatch repair genes. This study analyzed data from the...

Cite
Guerrini-Rousseau L, Varlet P, Colas C, et al. Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium. Neurooncol Adv. 2019;1(1):vdz033doi: 10.1093/noajnl/vdz033.
Guerrini-Rousseau, L., Varlet, P., Colas, C., Andreiuolo, F., Bourdeaut, F., Dahan, K., Devalck, C., Faure-Conter, C., Genuardi, M., Goldberg, Y., Kuhlen, M., Moalla, S., Opocher, E., Perez-Alonso, V., Sehested, A., Slavc, I., Unger, S., Wimmer, K., Grill, J., & Brugières, L. (2019). Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium. Neuro-oncology advances, 1(1), vdz033. https://doi.org/10.1093/noajnl/vdz033
Guerrini-Rousseau, Léa, et al. "Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium." Neuro-oncology advances vol. 1,1 (2019): vdz033. doi: https://doi.org/10.1093/noajnl/vdz033
Guerrini-Rousseau L, Varlet P, Colas C, Andreiuolo F, Bourdeaut F, Dahan K, Devalck C, Faure-Conter C, Genuardi M, Goldberg Y, Kuhlen M, Moalla S, Opocher E, Perez-Alonso V, Sehested A, Slavc I, Unger S, Wimmer K, Grill J, Brugières L. Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium. Neurooncol Adv. 2019 Dec 02;1(1):vdz033. doi: 10.1093/noajnl/vdz033. eCollection 2019. PMID: 32642664; PMCID: PMC7212899.
Copy Download .nbib Format: NLM
NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation.

Neuro-oncology advances

Lobón-Iglesias MJ, Laurendeau I, Guerrini-Rousseau L, Tauziède-Espariat A, Briand-Suleau A, Varlet P, Vidaud D, Vidaud M, Brugieres L, Grill J, Pasmant E.
PMID: 32642735
Neurooncol Adv. 2019 Dec 20;2:i98-i106. doi: 10.1093/noajnl/vdz054. eCollection 2020 Jul.

BACKGROUND: Pediatric neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) exhibit different clinico-radiological features, treatment, and outcome compared with sporadic OPGs. While NF1-associated OPGs are caused by complete loss-of-function of the METHODS: We analyzed clinico-radiological features of 16 children...

Cite
Lobón-Iglesias MJ, Laurendeau I, Guerrini-Rousseau L, et al. NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation. Neurooncol Adv. 2019;2:i98-i106doi: 10.1093/noajnl/vdz054.
Lobón-Iglesias, M. J., Laurendeau, I., Guerrini-Rousseau, L., Tauziède-Espariat, A., Briand-Suleau, A., Varlet, P., Vidaud, D., Vidaud, M., Brugieres, L., Grill, J., & Pasmant, E. (2020). NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation. Neuro-oncology advances, 2i98-i106. https://doi.org/10.1093/noajnl/vdz054
Lobón-Iglesias, María Jesús, et al. "NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation." Neuro-oncology advances vol. 2 (2020): i98-i106. doi: https://doi.org/10.1093/noajnl/vdz054
Lobón-Iglesias MJ, Laurendeau I, Guerrini-Rousseau L, Tauziède-Espariat A, Briand-Suleau A, Varlet P, Vidaud D, Vidaud M, Brugieres L, Grill J, Pasmant E. NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation. Neurooncol Adv. 2019 Dec 20;2:i98-i106. doi: 10.1093/noajnl/vdz054. eCollection 2020 Jul. PMID: 32642735; PMCID: PMC7317061.
Copy Download .nbib Format: NLM
Difficulties of Management of Multiple Synchronous Bone Tumors in Li-Fraumeni Syndrome.

Case reports in orthopedics

Huby M, Brugières L, Mascard E, Gaspar N, Pannier S, Aurégan JC.
PMID: 31827960
Case Rep Orthop. 2019 Nov 13;2019:8732089. doi: 10.1155/2019/8732089. eCollection 2019.

Li-Fraumeni syndrome is a rare inherited disease characterized by the early onset of multiple primary malignant tumors. Sarcomas account for more than 30% of all malignant tumors occurring at pediatric age. Furthermore, it was shown that the rates of...

Cite
Huby M, Brugières L, Mascard E, et al. Difficulties of Management of Multiple Synchronous Bone Tumors in Li-Fraumeni Syndrome. Case Rep Orthop. 2019;2019:8732089doi: 10.1155/2019/8732089.
Huby, M., Brugières, L., Mascard, E., Gaspar, N., Pannier, S., & Aurégan, J. C. (2019). Difficulties of Management of Multiple Synchronous Bone Tumors in Li-Fraumeni Syndrome. Case reports in orthopedics, 20198732089. https://doi.org/10.1155/2019/8732089
Huby, Marine, et al. "Difficulties of Management of Multiple Synchronous Bone Tumors in Li-Fraumeni Syndrome." Case reports in orthopedics vol. 2019 (2019): 8732089. doi: https://doi.org/10.1155/2019/8732089
Huby M, Brugières L, Mascard E, Gaspar N, Pannier S, Aurégan JC. Difficulties of Management of Multiple Synchronous Bone Tumors in Li-Fraumeni Syndrome. Case Rep Orthop. 2019 Nov 13;2019:8732089. doi: 10.1155/2019/8732089. eCollection 2019. PMID: 31827960; PMCID: PMC6885189.
Copy Download .nbib Format: NLM
The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey.

ESMO open

Saloustros E, Stark DP, Michailidou K, Mountzios G, Brugieres L, Peccatori FA, Jezdic S, Essiaf S, Douillard JY, Bielack S.
PMID: 29018578
ESMO Open. 2017 Sep 08;2(4):e000252. doi: 10.1136/esmoopen-2017-000252. eCollection 2017.

INTRODUCTION: Adolescents and young adults (AYA) with cancer require dedicated clinical management and care. Little is known about the training and practice of European healthcare providers in regard to AYA and the availability of specialised services.METHODS: A link to...

Cite
Saloustros E, Stark DP, Michailidou K, et al. The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. ESMO Open. 2017;2(4):e000252doi: 10.1136/esmoopen-2017-000252.
Saloustros, E., Stark, D. P., Michailidou, K., Mountzios, G., Brugieres, L., Peccatori, F. A., Jezdic, S., Essiaf, S., Douillard, J. Y., & Bielack, S. (2017). The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. ESMO open, 2(4), e000252. https://doi.org/10.1136/esmoopen-2017-000252
Saloustros, Emmanouil, et al. "The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey." ESMO open vol. 2,4 (2017): e000252. doi: https://doi.org/10.1136/esmoopen-2017-000252
Saloustros E, Stark DP, Michailidou K, Mountzios G, Brugieres L, Peccatori FA, Jezdic S, Essiaf S, Douillard JY, Bielack S. The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. ESMO Open. 2017 Sep 08;2(4):e000252. doi: 10.1136/esmoopen-2017-000252. eCollection 2017. PMID: 29018578; PMCID: PMC5604713.
Copy Download .nbib Format: NLM
CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial.

Oncoimmunology

Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Rédini F.
PMID: 28932633
Oncoimmunology. 2017 Aug 24;6(9):e1331193. doi: 10.1080/2162402X.2017.1331193. eCollection 2017.

The French phase 3 trial (OS 2006) testing zoledronic acid, an osteoclast inhibitor, with chemotherapy and surgery did not improve the outcome of patients with osteosarcoma (OS). To understand this unexpected result, the presence of infiltrating immune cells was...

Cite
Gomez-Brouchet A, Illac C, Gilhodes J, et al. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology. 2017;6(9):e1331193doi: 10.1080/2162402X.2017.1331193.
Gomez-Brouchet, A., Illac, C., Gilhodes, J., Bouvier, C., Aubert, S., Guinebretiere, J. M., Marie, B., Larousserie, F., Entz-Werlé, N., de Pinieux, G., Filleron, T., Minard, V., Minville, V., Mascard, E., Gouin, F., Jimenez, M., Ledeley, M. C., Piperno-Neumann, S., Brugieres, L., & Rédini, F. (2017). CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology, 6(9), e1331193. https://doi.org/10.1080/2162402X.2017.1331193
Gomez-Brouchet, Anne, et al. "CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial." Oncoimmunology vol. 6,9 (2017): e1331193. doi: https://doi.org/10.1080/2162402X.2017.1331193
Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Rédini F. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology. 2017 Aug 24;6(9):e1331193. doi: 10.1080/2162402X.2017.1331193. eCollection 2017. PMID: 28932633; PMCID: PMC5599091.
Copy Download .nbib Format: NLM
Bone sarcomas: from biology to targeted therapies.

Sarcoma

Gaspar N, Di Giannatale A, Geoerger B, Redini F, Corradini N, Enz-Werle N, Tirode F, Marec-Berard P, Gentet JC, Laurence V, Piperno-Neumann S, Oberlin O, Brugieres L.
PMID: 23226965
Sarcoma. 2012;2012:301975. doi: 10.1155/2012/301975. Epub 2012 Nov 27.

Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases which occur mainly in adolescents and young adults. With the current therapies, some patients remain very difficult to treat, such as tumour with poor histological response to preoperative...

Cite
Gaspar N, Di Giannatale A, Geoerger B, et al. Bone sarcomas: from biology to targeted therapies. Sarcoma. 2012;2012:301975doi: 10.1155/2012/301975.
Gaspar, N., Di Giannatale, A., Geoerger, B., Redini, F., Corradini, N., Enz-Werle, N., Tirode, F., Marec-Berard, P., Gentet, J. C., Laurence, V., Piperno-Neumann, S., Oberlin, O., & Brugieres, L. (2012). Bone sarcomas: from biology to targeted therapies. Sarcoma, 2012301975. https://doi.org/10.1155/2012/301975
Gaspar, Nathalie, et al. "Bone sarcomas: from biology to targeted therapies." Sarcoma vol. 2012 (2012): 301975. doi: https://doi.org/10.1155/2012/301975
Gaspar N, Di Giannatale A, Geoerger B, Redini F, Corradini N, Enz-Werle N, Tirode F, Marec-Berard P, Gentet JC, Laurence V, Piperno-Neumann S, Oberlin O, Brugieres L. Bone sarcomas: from biology to targeted therapies. Sarcoma. 2012;2012:301975. doi: 10.1155/2012/301975. Epub 2012 Nov 27. PMID: 23226965; PMCID: PMC3514839.
Copy Download .nbib Format: NLM
Hypoglycemia in infants.

Trends in endocrinology and metabolism: TEM

Zeller J, Bougnères P.
PMID: 18407123
Trends Endocrinol Metab. 1992 Dec;3(10):366-70. doi: 10.1016/1043-2760(92)90003-j.

Because the infant's brain is to a large extent dependent on glucose utilization, hypoglycemia of infants can have grave effects on brain function, and it is important to diagnose it and, when possible, treat it promptly. Causes of hypoglycemia...

Cite
Zeller J, Bougnères P. Hypoglycemia in infants. Trends Endocrinol Metab. 1992;3(10):366-70doi: 10.1016/1043-2760(92)90003-j.
Zeller, J., & Bougnères, P. (1992). Hypoglycemia in infants. Trends in endocrinology and metabolism: TEM, 3(10), 366-70. https://doi.org/10.1016/1043-2760(92)90003-j
Zeller, J, and Bougnères, P. "Hypoglycemia in infants." Trends in endocrinology and metabolism: TEM vol. 3,10 (1992): 366-70. doi: https://doi.org/10.1016/1043-2760(92)90003-j
Zeller J, Bougnères P. Hypoglycemia in infants. Trends Endocrinol Metab. 1992 Dec;3(10):366-70. doi: 10.1016/1043-2760(92)90003-j. PMID: 18407123.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 68 entries